All In Biotech

Drug Trial Radar · NCT02426684

Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.

Last checked: Nov 19, 2026Latest source record: May 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

17

Actual

Start

Jun 16, 2015

Primary completion

Nov 10, 2017

Study completion Nov 10, 2017

Sponsor

Lead sponsor
Cedars-Sinai Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hansa Biopharma AB
First posted
Apr 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation. We hope that IdeS® will help eliminate DSAs in HS patients who are DSA+ and flow cytometry (FCMX) crossmatch + at time of transplant. We plan to enroll a total of 20 patients. Patients will be followed for 6 months post administration of IdeS®.

Conditions

  • Renal Disease

Interventions

  • IdeS® (Imlifidase)Drug

    0.24mg/kg IdeS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Allograft RejectionTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.